Literature DB >> 22372638

Biomarkers and transcriptome profiling of lung cancer.

Hsuan-Yu Chen1, Sung-Liang Yu, Ker-Chau Li, Pan-Chyr Yang.   

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. High-throughput technologies such as microarrays provide an opportunity to explore biomarkers for cancer prevention, prognosis and treatment guidance. Recent studies have revealed many biomarkers with the potential for clinical application. However, major limitations still exist. Although useful data on cancer genomics has accumulated rapidly, there has also been a simultaneous tendency for amplification of the complex relationships among the enormous number of variables that need to be considered. Disentangling these complex gene-gene interactions requires new approaches to data analysis to reveal information that has been obscured by traditional methods. Here, we review the current findings on biomarker identification in lung cancer, address their limitations and discuss some future directions for improvements in this area of research.
© 2012 The Authors. Respirology © 2012 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22372638     DOI: 10.1111/j.1440-1843.2012.02154.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  12 in total

1.  Detecting subnetwork-level dynamic correlations.

Authors:  Yan Yan; Shangzhao Qiu; Zhuxuan Jin; Sihong Gong; Yun Bai; Jianwei Lu; Tianwei Yu
Journal:  Bioinformatics       Date:  2016-09-25       Impact factor: 6.937

Review 2.  Research status and funding trends of lung cancer biomarkers.

Authors:  Cui Li; Wei Hong
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 3.  Year in review 2012: lung cancer, respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging.

Authors:  José M Porcel; Chi Chiu Leung; Marcos I Restrepo; Kazuhisa Takahashi; Pyng Lee
Journal:  Respirology       Date:  2013-04       Impact factor: 6.424

Review 4.  Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Anthony J Alberg; Malcolm V Brock; Jean G Ford; Jonathan M Samet; Simon D Spivack
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

5.  Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma.

Authors:  Ya-Hsuan Chang; Chung-Ming Chen; Hsuan-Yu Chen; Pan-Chyr Yang
Journal:  Sci Rep       Date:  2015-06-04       Impact factor: 4.379

6.  Functional analysis of microRNA and transcription factor synergistic regulatory network based on identifying regulatory motifs in non-small cell lung cancer.

Authors:  Kening Li; Zihui Li; Ning Zhao; Yaoqun Xu; Yongjing Liu; Yuanshuai Zhou; Desi Shang; Fujun Qiu; Rui Zhang; Zhiqiang Chang; Yan Xu
Journal:  BMC Syst Biol       Date:  2013-11-07

7.  Triple-layer dissection of the lung adenocarcinoma transcriptome: regulation at the gene, transcript, and exon levels.

Authors:  Min-Kung Hsu; I-Ching Wu; Ching-Chia Cheng; Jen-Liang Su; Chang-Huain Hsieh; Yeong-Shin Lin; Feng-Chi Chen
Journal:  Oncotarget       Date:  2015-10-06

8.  Identification of a robust subpathway-based signature for acute myeloid leukemia prognosis using an miRNA integrated strategy.

Authors:  Huijuan Chang; Qiuying Gao; Wei Ding; Xueqin Qing
Journal:  PLoS One       Date:  2018-03-23       Impact factor: 3.240

9.  CD24+/CD38- as new prognostic marker for non-small cell lung cancer.

Authors:  Feridoun Karimi-Busheri; Aghdass Rasouli-Nia; Victoria Zadorozhny; Habib Fakhrai
Journal:  Multidiscip Respir Med       Date:  2013-10-05

Review 10.  Researches on Transcriptome Sequencing in the Study of Traditional Chinese Medicine.

Authors:  Jie Xin; Rong-Chao Zhang; Lei Wang; Yong-Qing Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.